Cargando…
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
Although ductal carcinoma in situ (DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need for prognostic markers that can distinguish harmless from p...
Autores principales: | Almekinders, Mathilde M. M., Schaapveld, Michael, Thijssen, Bram, Visser, Lindy L., Bismeijer, Tycho, Sanders, Joyce, Isnaldi, Edoardo, Hofland, Ingrid, Mertz, Marjolijn, Wessels, Lodewyk F. A., Broeks, Annegien, Hooijberg, Erik, Zwart, Wilbert, Lips, Esther H., Desmedt, Christine, Wesseling, Jelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985299/ https://www.ncbi.nlm.nih.gov/pubmed/33753731 http://dx.doi.org/10.1038/s41523-021-00232-w |
Ejemplares similares
-
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
por: Almekinders, Mathilde M., et al.
Publicado: (2022) -
Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019) -
Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis
por: Bismeijer, Tycho, et al.
Publicado: (2018) -
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
por: Lefrère, Hanne, et al.
Publicado: (2023) -
Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
por: Ragusi, Max A.A., et al.
Publicado: (2021)